Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 108

Results For "ED"

8108 News Found

Shilpa Medicare Analytical Services Division gets VAI status from USFDA after GMP inspection
Drug Approval | May 23, 2023

Shilpa Medicare Analytical Services Division gets VAI status from USFDA after GMP inspection

This is the second US FDA GMP inspection of this facility within one year


Zydus receives final approval from the USFDA for Ephedrine Sulfate Injection
Drug Approval | May 22, 2023

Zydus receives final approval from the USFDA for Ephedrine Sulfate Injection

Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States


Eris Lifesciences posts consolidated Q4FY23 PAT at Rs. 65.41 Cr
News | May 22, 2023

Eris Lifesciences posts consolidated Q4FY23 PAT at Rs. 65.41 Cr

Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023


Zydus Wellness' FY23 consolidated net sales up 12.8% at Rs. 2243 Cr
News | May 22, 2023

Zydus Wellness' FY23 consolidated net sales up 12.8% at Rs. 2243 Cr

Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in their respective categories as on March 2023


GlaxoSmithKline Pharmaceuticals posts consolidated Q4 FY2023 PAT at Rs. 133.43 Cr
News | May 22, 2023

GlaxoSmithKline Pharmaceuticals posts consolidated Q4 FY2023 PAT at Rs. 133.43 Cr

The company has reported total income of Rs. 815.11 crores during the period ended March 31, 2023


Mandaviya to inaugurate conference on 'India Pharma & India Medical Devices’ on May 26-27
Policy | May 22, 2023

Mandaviya to inaugurate conference on 'India Pharma & India Medical Devices’ on May 26-27

8th Edition of the event to promote India as a manufacturing hub of quality medical products in the Pharmaceutical and Medical Devices Sector


Alkem Laboratories posts Q4 FY23 consolidated PAT slides to Rs. 70.98 Cr
News | May 20, 2023

Alkem Laboratories posts Q4 FY23 consolidated PAT slides to Rs. 70.98 Cr

The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023


Granules India received ANDA approval for Venlafaxine ER capsules
Drug Approval | May 20, 2023

Granules India received ANDA approval for Venlafaxine ER capsules

Venlafaxine HCl extended-release capsules are indicated for the treatment of: Major Depressive Disorder


Venus Remedies recognized for R&D excellence by DSIR
News | May 19, 2023

Venus Remedies recognized for R&D excellence by DSIR

Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions


KIMS posts Q4FY23 consolidated PAT at Rs. 93.27 Cr
News | May 19, 2023

KIMS posts Q4FY23 consolidated PAT at Rs. 93.27 Cr

The company has reported total income of Rs. 580.81 crores during the period ended March 31, 2023